Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...

For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality companies can see their share prices grow by huge amounts. For example, the Acceleron ...

Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock performs well, when investors win, they can win big. Just think about the savvy ...

The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel. The drug showed initial promise for FSHD patients after it ...

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...

Acceleron Pharma ($XLRN) is in Phase III testing for its lead candidate that’s partnered with Celgene ($CELG). Now, it’s brought in a top commercial executive ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, but ...

(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Acceleron Pharma (XLRN +0.00%) hasn't generated much excitement for investors so far this year. The stock is down close to 5% year to date while the broader market indexes are up solidly. The biotech ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...

As the global energy need is rising, both public institutions and private companies have increased their efforts toward nuclear fusion. The latest headline grabber in this sphere is Acceleron Fusion, ...